J&J Predicts No Stelara Biosimilar Until 2025
After reaching patent settlements with biosimilar drug makers, the company expects to retain exclusivity of its top-selling drug longer than initially expected.
After reaching patent settlements with biosimilar drug makers, the company expects to retain exclusivity of its top-selling drug longer than initially expected.